Juno Therapeutics Gmbh

Shape Therapeutics Inc.

Richard Sullivan

Francois Vigneault

Rafael Ponce

Yiannis Savva

Christopher Nye

David Huss

Liana Stein

Anupama Lakshmanan

Susan Byrne

Provided are CCT5-binding molecules, including anti-CCT5 antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and conjugates comprising the anti-CCT5 binding molecules such as immunoconjugates and antibody-drug conjugates, and chimeric receptors comprising the anti-CCT5 binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-CCT5 antibodies or antigen-binding fragments thereof specifically bind to CCT5. Also provided are genetically engineered cells expressing the CARs or CCT5-binding molecules and uses thereof such as in adoptive cell therapy.

Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same

Disclosed herein are compositions that comprise engineered polynucleotides, pharmaceutical compositions comprising the same, methods of making the same, and methods of treatment comprising the compositions that comprise the engineered polynucleotides.

Therapeutic editing

Growing community of inventors

Seattle, WA, United States of America

Richard Sullivan